Articles
Mast Cell Activation Syndrome and Mastocytosis: Initial Treatment Options and Long-Term Management
Castells M, Butterfield J. Mast Cell Activation Syndrome and Mastocytosis: Initial Treatment Options and Long-Term Management. J Allergy Clin Immunol Pract. 2019;7(4):1097-1106. doi:10.1016/j.jaip.2019.02.002
Omalizumab effectively prevents recurrent refractory anaphylaxis in a patient with monoclonal mast cell activation syndrome.
Jagdis A, Vadas P. Omalizumab effectively prevents recurrent refractory anaphylaxis in a patient with monoclonal mast cell activation syndrome. Ann Allergy Asthma Immunol. 2014;113(1):115-116. doi:10.1016/j.anai.2014.05.001
Timing of response and long term efficacy of Omalizumab in non-clonal mast cell activation syndrome: A case series.
Caminati M, Olivieri E, Nalin F, et al. Timing of response and long term efficacy of Omalizumab in non-clonal Mast Cell Activation Syndrome: A case series. Eur J Intern Med. 2020;71:104-106. doi:10.1016/j.ejim.2019.11.010
Mast Cell Activation Disorders
Giannetti A, Filice E, Caffarelli C, Ricci G, Pession A (2021). This article provides an overview of recent scientific findings relating to mast cell disorders, with an emphasis on diagnostic criteria, variability in symptoms and therapeutic strategies for tackling MCAS. It highlights the fact that there is little consensus on biomarkers indicating MCAS and concludes that a more detailed knowledge of the syndrome is necessary for developing effective therapies.
Mast cell activation syndrome: Myths and realities
Zhang S, Bernstein JA. Mast cell activation syndrome: Myths and realities. Allergy Asthma Proc. 2021;42(3):198-204. doi:10.2500/aap.2021.42.210012
A case of neuropathic pain in monoclonal mast cell activation syndrome
Bay JL, Sedarsky KE, Petersen MM. A case of neuropathic pain in monoclonal mast cell activation syndrome. Ann Allergy Asthma Immunol. 2018;120(5):543-544. doi:10.1016/j.anai.2018.02.019
Gastrointestinal Involvement in Mast Cell Activation Disorder
Hsieh FH. Gastrointestinal Involvement in Mast Cell Activation Disorders. Immunol Allergy Clin North Am. 2018;38(3):429-441. doi:10.1016/j.iac.2018.04.008
A Review of the Dermatologic Symptoms of Idiopathic Mast Cell Activation Syndrome
Qureshi AA, Friedman AJ. A Review of the Dermatologic Symptoms of Idiopathic Mast Cell Activation Syndrome. J Drugs Dermatol. 2019;18(2):162-168.
Mast Cell Activation Syndrome: is Anaphylaxis part of the phenotype?
Sabato V, Michel M, Blank U, Ebo DG, Vitte J. Mast cell activation syndrome: is anaphylaxis part of the phenotype? A systematic review [published online ahead of print, 2021 Jul 20]. Curr Opin Allergy Clin Immunol. 2021;10.1097/ACI.0000000000000768. doi:10.1097/ACI.0000000000000768
Fatal anaphylaxis following a hornet sting in a yellow jacket venom-sensitized patient with undetected monoclonal mast cell activation syndrome and without previous history of a systemic sting reaction
Blank S, Pehlivanli S, Methe H, et al. Fatal anaphylaxis following a hornet sting in a yellow jacket venom-sensitized patient with undetected monoclonal mast cell activation syndrome and without previous history of a systemic sting reaction. J Allergy Clin Immunol Pract. 2020;8(1):401-403.e2. doi:10.1016/j.jaip.2019.06.021
Idiopathic Anaphylaxis: A Form of Mast Cell Activation Syndrome
Giannetti MP, Akin C, Castells M. Idiopathic Anaphylaxis: A Form of Mast Cell Activation Syndrome. J Allergy Clin Immunol Pract. 2020;8(4):1196-1201. doi:10.1016/j.jaip.2019.10.048
Mast Cell disorders and idiopathic anaphylaxis: Evaluation and Management
Khalid MB, Lieberman P. Mast cell disorders and idiopathic anaphylaxis: Evaluation and management. Allergy Asthma Proc. 2020;41(2):90-98. doi:10.2500/aap.2020.41.190023
Carbamazepine-induced Stevens-Johnson syndrome in a patient with history of methotrexate-induced mast cell activation syndrome
Zaalouk TM, Bitar ZI, Maadarani OS, Elhabibi ME. Carbamazepine-induced Stevens-Johnson syndrome in a patient with history of methotrexate-induced mast cell activation syndrome. Clin Case Rep. 2020;9(1):256-259. Published 2020 Nov 11. doi:10.1002/ccr3.3509
Survey of Mast Cell Mediator Levels from Patients Presenting with Symptoms of Mast Cell Activation
Butterfield JH. Survey of Mast Cell Mediator Levels from Patients Presenting with Symptoms of Mast Cell Activation. Int Arch Allergy Immunol. 2020;181(1):43-50. doi:10.1159/000503964
Patients with mast cell activation symptoms and elevated baseline serum tryptase level have unique bone marrow morphology
Giannetti MP, Akin C, Hufdhi R, et al. Patients with mast cell activation symptoms and elevated baseline serum tryptase level have unique bone marrow morphology. J Allergy Clin Immunol. 2021;147(4):1497-1501.e1. doi:10.1016/j.jaci.2020.11.017
Distinct Small Intestine Mast Cell Histologic Changes in Patients With Hereditary Alpha-tryptasemia and Mast Cell Activation Syndrome
Hamilton MJ, Zhao M, Giannetti MP, et al. Distinct Small Intestine Mast Cell Histologic Changes in Patients With Hereditary Alpha-tryptasemia and Mast Cell Activation Syndrome. Am J Surg Pathol. 2021;45(7):997-1004. doi:10.1097/PAS.0000000000001676
Pathogenic and diagnostic relevance of KIT in primary mast cell activation disorders
Muñoz-González JI, García-Montero AC, Orfao A, Álvarez-Twose I. PATHOGENIC AND DIAGNOSTIC RELEVANCE OF KIT IN PRIMARY MAST CELL ACTIVATION DISORDERS [published online ahead of print, 2021 Jul 20]. Ann Allergy Asthma Immunol. 2021;S1081-1206(21)00513-5. doi:10.1016/j.anai.2021.07.014
A distinct biomolecular profile identifies monoclonal mast cell disorders in patients with idiopathic anaphylaxis.
Carter MC, Desai A, Komarow HD, et al. A distinct biomolecular profile identifies monoclonal mast cell disorders in patients with idiopathic anaphylaxis. J Allergy Clin Immunol. 2018;141(1):180-188.e3. doi:10.1016/j.jaci.2017.05.036
Highly sensitive assays are mandatory for the differential diagnosis of patients presenting with symptoms of mast cell activation: diagnostic workup of 38 patients
Van den Poel B, Kochuyt AM, Del Biondo E, et al. Highly sensitive assays are mandatory for the differential diagnosis of patients presenting with symptoms of mast cell activation: diagnostic work-up of 38 patients. Acta Clin Belg. 2017;72(2):123-129. doi:10.1080/17843286.2017.1293312
The Utility of Measuring Urinary Metabolites of Mast Cell Mediators in Systemic Mastocytosis and Mast Cell Activation Syndrome
Butterfield J, Weiler CR. The Utility of Measuring Urinary Metabolites of Mast Cell Mediators in Systemic Mastocytosis and Mast Cell Activation Syndrome. J Allergy Clin Immunol Pract. 2020;8(8):2533-2541. doi:10.1016/j.jaip.2020.02.021
Become a friend
Sign up to become a Friend of Mast Cell Action so we can keep you up to date on our progress and on how to get involved in our latest campaigns and initiatives.
Donate
Mast Cell Action relies entirely on the generosity of people like you. Please make a donation now and together we can make a difference to those affected by MCAS.
